Bai Ausaitu: The first-instance judgment of litigation rejection of plaintiff and Bo Medical's lawsuit request.

The announcement from Bai Ausaitu stated that on September 4, 2024, Hebo Pharmaceuticals sued the company, claiming that the RenNano platform and antibody products infringed on its patents, seeking a claim of 1 million yuan; on November 5, 2025, Hebo Pharmaceuticals filed another lawsuit, seeking a claim of 10 million yuan. On June 29, 2026, the Shanghai Intellectual Property Court issued a first-instance judgment, rejecting Hebo Pharmaceuticals' lawsuit request. The company stated that this lawsuit did not have a significant adverse impact on its production and operation, and it will continue to maintain research and development investment.